DK1261602T3 - Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer - Google Patents

Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer

Info

Publication number: DK1261602T3
Authority: DK; Denmark
Prior art keywords: sub; sup; alkyl; hydrogen; optionally substituted
Prior art date: 2000-03-06

Application number

DK01907980T

Other languages

English (en)

Inventor

Alessandra Gaiba

Andrew Kenneth Takle

David Matthew Wilson

Original Assignee

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-06

Filing date

2001-03-02

Publication date

2004-08-30

2001-03-02 Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc

2004-08-30 Application granted granted Critical

2004-08-30 Publication of DK1261602T3 publication Critical patent/DK1261602T3/da

Links

102000009929 raf Kinases Human genes 0.000 title abstract 2
108010077182 raf Kinases Proteins 0.000 title abstract 2
NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical class NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 10
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000003118 aryl group Chemical group 0.000 abstract 3
125000001072 heteroaryl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical class 0.000 abstract 3
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
125000002950 monocyclic group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK01907980T 2000-03-06 2001-03-02 Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer DK1261602T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0005357.9A GB0005357D0 (en)	2000-03-06	2000-03-06	Compounds
PCT/GB2001/000916 WO2001066540A1 (en)	2000-03-06	2001-03-02	Imidazol-2-carboxamide derivatives as raf kinase inhibitors

Publications (1)

Publication Number	Publication Date
DK1261602T3 true DK1261602T3 (da)	2004-08-30

Family

ID=9887051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01907980T DK1261602T3 (da)	2000-03-06	2001-03-02	Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer

Country Status (12)

Country	Link
US (1)	US6987119B2 (da)
EP (1)	EP1261602B1 (da)
JP (1)	JP2003525937A (da)
AT (1)	ATE266021T1 (da)
AU (1)	AU2001235844A1 (da)
DE (1)	DE60103133T2 (da)
DK (1)	DK1261602T3 (da)
ES (1)	ES2217118T3 (da)
GB (1)	GB0005357D0 (da)
PT (1)	PT1261602E (da)
TR (1)	TR200401903T4 (da)
WO (1)	WO2001066540A1 (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en)	1999-01-13	2013-10-08	Bayer Healthcare Llc	.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7189745B1 (en)	1999-11-22	2007-03-13	Smithkline Beecham Corporation	Compounds
DE60103136T2 (de) *	2000-03-06	2004-10-28	Smithkline Beecham Plc, Brentford	Imidazolderivate als Raf-Kinase Inhibitoren
GB0112348D0 (en)	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
GB0121494D0 (en)	2001-09-05	2001-10-24	Smithkline Beecham Plc	Compounds
EP1432699A1 (en) *	2001-09-05	2004-06-30	Smithkline Beecham Plc	Pyridylfurans and pyrroles as raf kinase inhibitors
GB0121488D0 (en)	2001-09-05	2001-10-24	Smithkline Beecham Plc	Compounds
EP1432703A1 (en) *	2001-09-05	2004-06-30	Smithkline Beecham Plc	Heterocycle-carboxamide derivatives as raf kinase inhibitors
EP2324825A1 (en)	2002-02-11	2011-05-25	Bayer Healthcare LLC	Aryl ureas with angiogenesis inhibiting activity
AR038966A1 (es) *	2002-03-18	2005-02-02	Solvay Pharm Bv	Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
WO2004019873A2 (en)	2002-08-29	2004-03-11	Scios Inc.	Methods of promoting osteogenesis
DE602004007382T2 (de)	2003-05-20	2008-04-17	Bayer Pharmaceuticals Corp., West Haven	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da)	2003-07-23	2008-04-07	Bayer Pharmaceuticals Corp	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US7244441B2 (en)	2003-09-25	2007-07-17	Scios, Inc.	Stents and intra-luminal prostheses containing map kinase inhibitors
US20050282909A1 (en) *	2003-11-14	2005-12-22	Diks Sander H	Guanylhydrazones in methods of treatment or diagnosis as modulators of signal transduction
MX2007002434A (es) *	2004-08-31	2007-05-04	Astrazeneca Ab	Derivados de quinazolinona y su uso como inhibidores de b-raf.
WO2006024836A1 (en) *	2004-09-01	2006-03-09	Astrazeneca Ab	Quinazolinone derivatives and their use as b-raf inhibitors
EP1676574A3 (en)	2004-12-30	2006-07-26	Johnson & Johnson Vision Care, Inc.	Methods for promoting survival of transplanted tissues and cells
EP1951234A2 (en) *	2005-10-18	2008-08-06	Janssen Pharmaceutica N.V.	Method of inhibiting flt3 kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
EP2016070B1 (en)	2006-04-20	2016-01-13	Janssen Pharmaceutica N.V.	Inhibitors of c-fms kinase
CL2008001626A1 (es)	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
US20100190777A1 (en)	2007-07-17	2010-07-29	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
JP5270553B2 (ja)	2007-08-23	2013-08-21	武田薬品工業株式会社	複素環化合物およびその用途
JP5350247B2 (ja)	2007-08-29	2013-11-27	武田薬品工業株式会社	複素環化合物およびその用途
BRPI0908906A2 (pt) *	2008-03-21	2019-09-24	Novartis Ag	compostos heterocíclicos e usos dos mesmos
US8865732B2 (en)	2008-03-21	2014-10-21	Novartis Ag	Heterocyclic compounds and uses thereof
US8697874B2 (en)	2008-12-01	2014-04-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JO3101B1 (ar)	2008-12-02	2017-09-20	Takeda Pharmaceuticals Co	مشتقات بنزوثيازول كعوامل مضادة للسرطان
KR20140011780A (ko) *	2012-07-19	2014-01-29	한미약품 주식회사	단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
EP3046557A1 (en)	2013-09-20	2016-07-27	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
US20170027940A1 (en)	2014-04-10	2017-02-02	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
UY36294A (es)	2014-09-12	2016-04-29	Novartis Ag	Compuestos y composiciones como inhibidores de quinasa
EP3515446B1 (en)	2016-09-19	2023-12-20	Novartis AG	Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
US11266653B2 (en)	2017-05-02	2022-03-08	Novartis Ag	Combination therapy
ES3025633T3 (en)	2019-05-13	2025-06-09	Novartis Ag	New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2026041859A1 (en) *	2024-08-19	2026-02-26	Oxford University Innovation Limited	Pak1 and/or pak2 activators and their use in the prevention and/or treatment of diseases or conditions

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1175431A (en)	1980-07-25	1984-10-02	Alfred Sallmann	Tri-substituted imidazole derivatives, processes for their manufacture, pharmaceutical preparations containing them, and their use
US5236917A (en)	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5514505A (en)	1995-05-15	1996-05-07	Xerox Corporation	Method for obtaining improved image contrast in migration imaging members
CA2224563A1 (en)	1995-06-12	1996-12-27	G.D. Searle & Co.	Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US5717100A (en)	1995-10-06	1998-02-10	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
DE69637948D1 (de)	1995-10-06	2009-07-23	Merck & Co Inc	Substituierte imidazole mit krebsremmender und cytokininhibierender wirkung
GB2306108A (en)	1995-10-13	1997-04-30	Merck & Co Inc	Treatment of Raf-mediated cancers with imidazole derivatives
JP2000504023A (ja)	1996-04-03	2000-04-04	メルクエンドカンパニーインコーポレーテッド	癌治療方法
EP0906307B1 (en)	1996-06-10	2005-04-27	Merck & Co., Inc.	Substituted imidazoles having cytokine inhibitory activity
WO1998016227A1 (en)	1996-10-15	1998-04-23	G.D. Searle & Co.	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6040320A (en)	1997-06-30	2000-03-21	Ortho-Mcneil Pharmaceutical, Inc.	2-substituted imidazoles useful in the treatment of inflammatory diseases
ATE257703T1 (de)	1997-10-27	2004-01-15	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
EP1049664B1 (en)	1997-12-22	2005-03-16	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
NZ526958A (en)	1998-05-22	2004-12-24	Smithkline Beecham Corp	Novel 2-alkyl substituted imidazole compounds
US7189745B1 (en)	1999-11-22	2007-03-13	Smithkline Beecham Corporation	Compounds
WO2002039954A2 (en)	2000-11-20	2002-05-23	Smithkline Beecham Corporation	Novel compounds

2000
- 2000-03-06 GB GBGB0005357.9A patent/GB0005357D0/en not_active Ceased
2001
- 2001-03-02 ES ES01907980T patent/ES2217118T3/es not_active Expired - Lifetime
- 2001-03-02 EP EP01907980A patent/EP1261602B1/en not_active Expired - Lifetime
- 2001-03-02 JP JP2001565356A patent/JP2003525937A/ja not_active Withdrawn
- 2001-03-02 DK DK01907980T patent/DK1261602T3/da active
- 2001-03-02 DE DE60103133T patent/DE60103133T2/de not_active Expired - Fee Related
- 2001-03-02 PT PT01907980T patent/PT1261602E/pt unknown
- 2001-03-02 WO PCT/GB2001/000916 patent/WO2001066540A1/en not_active Ceased
- 2001-03-02 TR TR2004/01903T patent/TR200401903T4/xx unknown
- 2001-03-02 AU AU2001235844A patent/AU2001235844A1/en not_active Abandoned
- 2001-03-02 AT AT01907980T patent/ATE266021T1/de not_active IP Right Cessation
- 2001-03-02 US US10/220,675 patent/US6987119B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6987119B2 (en)	2006-01-17
EP1261602B1 (en)	2004-05-06
EP1261602A1 (en)	2002-12-04
US20030134837A1 (en)	2003-07-17
DE60103133D1 (de)	2004-06-09
TR200401903T4 (tr)	2004-09-21
ATE266021T1 (de)	2004-05-15
PT1261602E (pt)	2004-08-31
AU2001235844A1 (en)	2001-09-17
ES2217118T3 (es)	2004-11-01
JP2003525937A (ja)	2003-09-02
DE60103133T2 (de)	2004-10-14
GB0005357D0 (en)	2000-04-26
WO2001066540A1 (en)	2001-09-13

Publication	Publication Date	Title
TR200401903T4 (tr)	2004-09-21	Raf kınaz tesir önleyici olarak imidazol-2-karboksamid türevleri.
ATE266022T1 (de)	2004-05-15	Imidazol derivate als raf kinase inhibitoren
EP1724262A4 (en)	2009-10-21	1- (2H) -ISOCHINOLONDERIVAT
RU2007110629A (ru)	2008-10-27	Ингибиторы днк-пк
EA200970461A1 (ru)	2009-12-30	ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 3-ИЗОБУТИЛ-9,10-ДИМЕТОКСИ-1,3,4,6,7,11b-ГЕКСАГИДРО-2Н-ПИРИДО[2,1-a]ИЗОХИНОЛИН-2-ОЛА И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA200602060A1 (ru)	2007-04-27	Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
SE0202463D0 (sv)	2002-08-14	Novel compounds
NO20082101L (no)	2008-08-15	Pyrido-, pyrazo- og pyrimido-pyrimidinderivater som mTor inhibitorer
TNSN03110A1 (en)	2005-12-23	Azaindoles.
HRP20040429B1 (hr)	2007-10-31	Derivati sulfonamida, njihova priprema i upotrebakao lijekova
EP1939175A4 (en)	2009-07-22	SULFONAMIDE DERIVATIVITY WITH PGD2 RECEPTOR ANTAGONISTIC EFFECT
AR029216A1 (es)	2003-06-18	Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
EA200601235A1 (ru)	2006-12-29	Производные тиазола
NO20060145L (no)	2006-03-07	Substituerte indazolyl (indolyl) maleimidderivater som kinase inhibitorer
EE200200148A (et)	2003-04-15	Kinasoliini derivaadid, nende valmistamise meetodning kasutamine
NO20063231L (no)	2006-07-11	Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
DE60225671D1 (de)	2008-04-30	Pharmazeutisch wirksame piperidinderivate
HUP0400246A2 (hu)	2004-08-30	1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
SE0400284D0 (sv)	2004-02-10	Novel compounds
CY1106522T1 (el)	2012-01-25	Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
UA100003C2 (ru)	2012-11-12	Соединения 1,2,4,5-тетрагидро-3н-бензазепина, способ их получения и фармацевтическая композиция, которая их содержит
ATE403653T1 (de)	2008-08-15	Pyridin-substituierte furanderivate als raf- kinase inhibitoren
DK1320526T3 (da)	2010-10-18	Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser
AR047531A1 (es)	2006-01-25	Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
EP1854789A4 (en)	2009-06-17	CHINAZOLINE DERIVATIVE WITH TYROSINE KINASE HEMMENDER EFFECT